description
Activating point mutations in FGFR3 are found in the extracellular ligand-binding domain, the transmembrane region and the tyrosine kinase domain and are believed to result in ligand-independent activation of the receptor (Webster and Donoghue, 1996; Wenbster, 1997). These mutations, although initially characterized in the context of autosomal skeletal disorders, are now being identified in a range of cancers including bladder, cervical, breast, prostate, head and neck, and multiple myeloma (reviewed in Wesche, 2011)

external resources
NCBI:1268875
REACTOME:R-HSA-1839130
PUBMED:21711248
PUBMED:8599935
PUBMED:8754806

genes
FGF1 , FGF2 , FGF4 , FGF5 , FGF8 , FGF9 , FGFR3 , FGF23 , FGF18 , FGF17 , FGF16 , FGF20 ,